http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11478450-B2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_67dd1f39f37bac4617e37d6d5c60aa8b
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4152
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4152
filingDate 2021-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2022-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e11a74a4d8f71c4f395d2e551f7151f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_647bd03e98816aa7c90251e5ec59e7b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4e9df0c012636dbf580350ef4eefe59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f15e72837fb653887282bba820b0933e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30f097aa8b49de08ab49a31487afddda
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_193322c2db712294824ee6fae4e6bcfe
publicationDate 2022-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-11478450-B2
titleOfInvention Edaravone suspension for oral administration
abstract An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021251965-A1
priorityDate 2018-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021009775-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019328711-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11241416-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019083490-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H1129463-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014177415-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018134243-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10987341-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018133957-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2004091441-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012056950-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020138712-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419497836
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4021

Total number of triples: 47.